Airway disease does not respect neat diagnostic boundaries. Asthma, COPD, allergic rhinitis and small‑airway dysfunction often overlap, sharing triggers and patient experiences. Yet most long‑term studies have treated them in isolation, focusing narrowly on severe cases and missing the broader picture. The result is a fragmented understanding of airway disease biology and progression - and a missed opportunity to design better therapies.
The MAPLE‑UK study was established to change this. MAPLE-UK is a five‑year, prospective, observational platform that follows patients across the full spectrum of airway disease. It combines annual full‑day clinics with six‑month virtual check‑ins and real‑time assessments during colds or exacerbations. By capturing lung function, biomarkers, exacerbation triggers and patient‑reported outcomes, MAPLE-UK builds a living picture of how airway disease evolves in the real world.
What makes MAPLE-UK distinctive is its focus on the mild to moderate patients who represent most of the population but are under‑represented in research. These patients experience frequent exacerbations, often triggered by viral infections or allergens, yet their disease trajectories are poorly documented. MAPLE-UK’s design ensures those events are captured prospectively, linked to baseline biology and tracked over time. Such data are invaluable for understanding when and how interventions can make the greatest difference.
MAPLE-UK is more than a study — it is infrastructure. The cohort is deeply phenotyped and endotyped, differentiating T2‑high from non‑T2 inflammation, mapping small‑airway dysfunction and recording comorbidities and environmental influences. This creates a trial‑ready population that sponsors can access quickly and reliably, reducing recruitment delays and screening failures. It also provides a foundation for sub‑studies, from allergen and viral challenges to device validation and biomarker testing, making MAPLE-UK a collaborative platform for pharmaceutical companies, biotech and academia.
The implications extend beyond asthma. MAPLE-UK is already expanding into COPD and other airway diseases, and its methodology is transferable to chronic conditions more broadly. By integrating biology, behaviour and environment over time, MAPLE-UK offers a blueprint for how research can evolve: moving from reactive recruitment to proactive characterisation, and from isolated studies to connected platforms.
Airway disease is complex, but MAPLE-UK makes it comprehensible. By capturing the realities of patients’ lives and linking them to rigorous science, MAPLE-UK provides the insights needed to design smarter trials, develop better therapies and ultimately improve outcomes. It is not only about studying disease — it is about building the future of respiratory research.